Theranica, a Netanya, Israel-based bio-medical technology company developing advanced electroceuticals for migraine and other prevalent diseases, raised $35m in Series B funding.
The round was led by aMoon with participation from existing investors Lightspeed Venture Partners, LionBird, Corundum Open Innovation and Takoa.
Founded in 2016 by Alon Ironi, Ronen Jashek, Rotislav (Slava) Barabash and Dr. Shimon Eckhouse, Theranica is a bio-medical technology company developing advanced electroceuticals for migraine and other prevalent diseases. Nerivio Migra®, the company’s novel remote neuromodulation device for acute treatment of migraine, is currently under review of the FDA.
In October 2018, Theranica completed a pivotal study with the device, spanning 12 clinical sites in the US and Israel, with almost 300 migraine patients. The study met its primary endpoint with high statistical significance, and demonstrated high efficacy, safety and tolerability.
The new funds will allow the company to mass-produce the Nerivio Migra®, and – once cleared by the FDA – to deliver the device to millions of migraine patients in the USA.
The Nerivio Migra is Investigational Device, Currently Limited by US Federal Law to Investigational Use Only in the United States.